Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in Bipolar-I Disorder with Mania (BALSAM-1)
NCT06951698Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of xanomeline in bipolar I disorder, sponsored by Bristol Myers Squibb. Started Jun 2025; status: recruiting.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT06951698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951698.